Atrasentan in Treating Patients With Prostate Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of hormone-refractory prostate cancer
• •Completed protocol ABBOTT-M00-211 or ABBOTT-M00-244 within the past 30 days
• •* Disease progression OR
• •* Active in trial when double-blind treatment period ended
• •PATIENT CHARACTERISTICS:
• •Age
• •19 and over
• •Performance status
• •Karnofsky 60-100%
• •Life expectancy
• •Not specified
• •Hematopoietic
• •WBC at least 3,000/mm3
• •Absolute neutrophil count greater than 1,000/mm3
• •Platelet count at least 100,000/mm3
• •Hemoglobin at least 9 g/dL
• •Hepatic
• •Bilirubin less than 1.5 mg/dL
• •AST and ALT no greater than 1.5 times upper limit of normal
• •Renal
• •Creatinine clearance at least 40 mL/min
• •Cardiovascular
• •No New York Heart Association class II-IV heart disease
• •Pulmonary
• •No significant pulmonary disease requiring chronic or pulse steroid therapy within the past 3 months
• •Other
• •Fertile patients must use 2 effective methods of contraception (1 must be barrier contraception) during and for 8 weeks after study
• •No reason that would preclude study
• •No significant comorbid condition that would preclude study
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •At least 4 weeks since other prior cytotoxic chemotherapy
• •No other concurrent cytotoxic chemotherapy
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •At least 4 weeks since prior radionuclides
• •No concurrent radionuclides
• •Surgery
• •Not specified
• •Other
• •At least 4 weeks since prior investigational agents
• •No concurrent antiretroviral therapy for HIV-positive patients
• •No concurrent participation in another investigational study